NHS patients will miss out on Wegovy as private clinics stock up on ‘miracle’ weight loss drug, doctors warn

• The NHS says the ‘miracle’ fat-busting jabs could help 50,000 adults lose weight
• But tens of thousands have already joined private waiting lists at pharmacies
• READ MORE: ‘Fake’ Wegovy warning as opportunistic sellers flood social media

NHS patients will miss out on ‘game changer’ slimming jab Wegovy as private providers are being prioritised over the health service, medics have warned.

On Monday it was announced that Brits could now access Wegovy via specialist NHS weight management services, as part of a ‘controlled and limited launch’. 

When it is fully rolled-out, it could help up to 50,000 patients lose weight, terbinafine keratin according to the health service.

But Novo Nordisk, the Danish pharma giant behind the ‘miracle’ drug, has already admitted that just a ‘proportion’ of already limited stock will be shared with the health service, with the rest allocated to private firms.

Experts hit out at the move, arguing that ‘doesn’t make sense’ and will leave those most in need without access to Wegovy.

On Monday it was announced that Brits could now access Wegovy via specialist health service weight management services, as part of a ‘controlled and limited launch’

When it is fully rolled-out, it could help up to 50,000 patients lose weight, according o the NHS. But Wegovy manufacturer, Novo Nordisk, has already admitted that just a ‘proportion’ of already limited stock will be shared with the health service. The rest will be allocated to private firms. Pictured, Simple Online Pharmacy unpacks Wegovy stock at its headquarters in Glasgow yesterday 

Professor Naveed Sattar, a consultant in metabolic medicine at the University of Glasgow, said he was ‘not comfortable’ with Wegovy being available privately.

He added: ‘It just doesn’t make sense to me because there is substantial need in the NHS. Why wouldn’t we put all that [supply] through the NHS?’

Professor Richard Holt, an expert in diabetes and endocrinology at the University of Southampton, said: ‘Using private providers will almost certainly mean that some of those who need the drug most will not be able obtain the drug.’

Semaglutide and liraglutide — the powerful ingredients behind Wegovy, Ozempic and Saxenda — have ushered in a new era in the war on obesity. 

The treatments spur weight loss by mimicking the actions of a hormone released in the gut after eating, called GLP-1.

Read more: Warning over ‘fake’ Wegovy as opportunistic sellers flood social media to fill demand as UK officially launched the fat-busting jab

As well as telling the pancreas to make more insulin, the GLP-1 hormone feeds back to the brain and makes users feel full. 

But such drugs are not without side effects. 

Users commonly complain of nausea, constipation and diarrhoea after taking the medication. 

Wegovy was approved as a drug specifically for weight loss in the US in 2021.

It was given the green light in Britain this year for the same reason. 

After its launch on Monday, the NHS confirmed that only Brits with a body mass index (BMI) over 30, or a BMI of more than 27 and at least one weight-related co-morbidity, are eligible – and patients must also commit to dieting and exercise plans. 

On the NHS, Wegovy costs the standard prescription rate of £9.65. 

Many will not pay the prescription charge because the eligibility for the drug includes co-morbidity, according to the NHS. 

People are entitled to free prescriptions if they meet one or more exemption categories. 

Among the qualifying criteria includes a continuing physical disability that prevents them going out without help from another person or having a specified medical condition. Both must have valid medical exemption certificates.  

But the jab could cost between £199 and £299 for those with private insurance or paying out of their own pocket. 

Ozempic, the other branded version of semaglutide which also triggers weight loss, is available only to people with type 2 diabetes. 

Last month, major shortages of Wegovy due to soaring demand delayed the £40million pilot scheme.

The National Institute for Care and Excellence (NICE), which publishes heath guidelines, has advised that patients should only use Wegovy for a ‘maximum’ of two years. 

This is despite experts saying people will need to take the drug for life. 

Despite being hailed as one of the most powerful pharmaceutical tools to date, experts have warned it is not a ‘magic pill’ or miracle fix all. Trials have shown that users can rapidly pile pounds back on once they stop taking the drug and it can trigger a variety of nasty side effects. Users commonly complain of nausea, constipation and diarrhoea

Wegovy and Ozempic, which both contain semaglutide, work by triggering the body to produce a hormone called glucagon-like peptide-1 that is released naturally from the intestines after meals

Novo Nordisk said it still expects supplies of the drug to be ‘constrained for the foreseeable future’. 

As a result, only a ‘proportion’ has been allocated to NHS services.

Tens of thousands have already joined waiting lists for pharmacies which are receiving stocks of Wegovy, to sell through online doctor services. 

These include Superdrug, which said that more than 20,000 have registered interest, and they will be contacted in the order they registered their interest. 

A month’s supply of Wegovy will cost between £195 and £295 from Superdrug. 

Boots Online Doctor said that prescriptions of Wegovy will initially only be available to patients already using their weight-loss treatment service, with prices starting at £199 a month.

Private online weight management clinic Juniper also confirmed on Monday that it will be providing Wegovy privately. 

It said it will be prioritising supply as it comes available to those on their waitlist.

Simple Online Pharmacy, based in the UK, also revealed more than 50,000 people had registered an interest in Wegovy on its website.

It confirmed the drug would cost between £199 and £299 a month.

It comes as pharmacists have already warned people to not buy weight loss jabs, like Wegovy, online over concerns they could cause serious harm and ‘damage major organs’. 

Adverts selling ‘weight loss pens’ and ‘skinny jabs’ have flooded social media in response to huge demand from Brits.

A UK study found that people who used Wegovy experienced rapid weight loss, dropping 18% of their weight over 68 weeks. They regained two-thirds of that weight, or 12% of their original body weight in the year after dropping the weekly injections

Sellers on Facebook Marketplace are listing weight loss jabs for sale without the need for a prescription. One seller shows an image of a fridge full of medication and lists the weight loss jabs for £130, pictured left. Another seller lists semaglutide, a drug found in both Ozempic and Wegovy, pictured right

MailOnline found several adverts on Facebook Marketplace selling weight loss jabs claiming to contain semaglutide, the ingredient in both Wegovy and it sister medication Ozempic. 

One seller listed Ozempic for £150, another shows an image of a fridge full of weight loss medication listing ‘weight loss pens’ for £130 and another selling a ‘skinny kit’ for £185. 

Private pharmacies online list Ozempic for between £150 and £170, to buy with a prescription. 

Lack of exercise, combined with unhealthy diets, have been blamed for the growing obesity epidemic in the UK. 

Latest NHS data shows 26 per cent of adults in England are obese and a further 38 per cent are overweight but not obese. 

A landmark study published in May also revealed UK’s bulging waistline is stripping billions of pounds from the cash-strapped NHS each year, with twice as much spent on obese patients, as on those of a healthy weight.

Costs per patient rise drastically the more people weigh, as they ‘collect obesity-related conditions’ such as type 2 diabetes, cancer and heart disease, according to research involving nearly 2.5million people. 

Source: Read Full Article